Sarcio uses regenerative cartilage cell therapy to treat patients suffering from the effects of Osteoarthritis.
Sarcio has raised $608K in total funding. The most recent round was Seed. The last funding was announced in July 2023.
Sarcio's investors include Groove Capital.
Sarcio is headquartered in Minneapolis, United States.
Sarcio uses regenerative cartilage cell therapy to treat patients suffering from the effects of Osteoarthritis.
Sarcio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sarcio — Funding & Investors." VCBacked, July 17, 2023, https://www.vcbacked.co/company/sarcio. Accessed July 19, 2026.
VCBacked. (2023). Sarcio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/sarcio
{{cite web |title=Sarcio — Funding & Investors |url=https://www.vcbacked.co/company/sarcio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated